Market for CAR-Ts Still Bright Despite FDA Cancer Safety Review

After the FDA announced in November that multiple CAR T cell therapies were under review for potential safety concerns, shares of several relevant biopharma firms dropped. Giants like Gilead Sciences and Bristol Myers-Squibb, as well as smaller companies such as Cabaletta Bio were affected. Shares of the big companies have since climbed back but remain largely flat, perhaps reflecting some hesitation among investors.